Asset profile
Migalastat · Galafold
Small molecule
Evidence outlook
Approved: Fabry Disease
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Weak signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
3 competitors in this universe: 1 direct rival (same mechanism and indication), 0 same-class, 2 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Migalastat (Galafold): this drug | Approved | Small molecule | Alpha-galactosidase A (GLA / α-Gal A) | ||
| Agalsidase Beta (Fabrazyme) | Approved | Protein / enzyme therapeutic | Alpha-galactosidase A (GLA / α-Gal A) | ||
| Pegunigalsidase Alfa | Approved | Protein / enzyme therapeutic | — | ||
| Isaralgagene Civaparvovec | Not yet studied | Gene therapy / editing | — |
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.